Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

被引：12
|
作者：
Ahn, M-J. [1 ]
Lisberg, A. E. [2 ]
Paz-Ares, L. [3 ]
Cornelissen, R. [4 ]
Girard, N. [5 ]
Pons-Tostivint, E. [6 ]
Vicente Baz, D. [7 ]
Sugawara, S. [8 ]
Cobo Dols, M. [9 ]
Perol, M. [10 ]
Mascaux, C. [11 ]
Poddubskaya, E. [12 ]
Kitazono, S. [13 ]
Hayashi, H. [14 ]
Sands, J. [15 ]
Hall, R. [16 ]
Zhang, Y. [17 ]
Zebger-Gong, H. [18 ]
Uema, D. [19 ]
Okamoto, I. [20 ]
机构：
[1] Samsung Med Ctr, Dept Med, Seoul, South Korea
[2] UCLA, Med David Geffen Sch Med, Los Angeles, CA USA
[3] Hosp Univ 12 Octubre, Med Oncol Dept Edificio Maternidad 2a Planta, Madrid, Spain
[4] Erasmus MC, Univ Med Ctr, Pulm Med, Rotterdam, Netherlands
[5] Inst Curie, Thorax Inst, Paris, France
[6] Univ Hosp Nantes, Dept Med Oncol, Nantes, France
[7] Hosp Univ Virgen Macarena, Med Oncol, Seville, Spain
[8] Sendai Kousei Hosp, Pulm Med Dept, Sendai, Miyagi, Japan
[9] Reg & Virgen Victoria Univ Hosp, Med Oncol Interctr Unit, IBIMA, Dept Med Oncol, Malaga, Spain
[10] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[11] Univ Hosp Strasbourg, Dept Pulm, Strasbourg, France
[12] Vitamed LLC, Moscow, Russia
[13] Canc Inst Hosp JFCR, Thorac Med Oncol Dept, Koto Ku, Tokyo, Japan
[14] Kindai Univ, Sch Med Main Campus, Osaka, Japan
[15] Harvard Med Sch, Dana Farber Canc Inst, Thorac Med Oncol, Boston, MA USA
[16] Univ Virginia, Hematooncol Dept, Charlottesville, VA USA
[17] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[18] Dauchi Sankyo Europe GmbH, Global Oncol Clin Dev, Munich, Germany
[19] Daiichi Sankyo USA, Oncol Res & Dev Dept, Parsippany, NJ USA
[20] Kyushu Univ, Dept Resp Med, Fukuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
509MO
引用
收藏
页码：S1665 / S1666
页数：2
相关论文
共 50 条
  • [1] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
    Ahn, M. J.
    Lisberg, A.
    Paz-Ares, L.
    Cornelissen, R.
    Girard, N.
    Pons-Tostivint, E.
    Baz, D. Vicente
    Sugawara, S.
    Dols, M. Cobo
    Perol, M.
    Mascaux, C.
    Poddubskaya, E.
    Kitazono, S.
    Hayashi, H.
    Sands, J.
    Hall, R.
    Zhang, Y.
    Zebger-Gong, H.
    Uema, D.
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2023, 34 : S1305 - S1306
  • [2] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
    Atmaca, Akin
    Ahn, Myung-Ju
    Lisberg, Aaron
    Paz-Ares, Luis
    Cornelissen, Robin
    Girard, Nicolas
    Pons-Tostivint, Elvire
    Baz, David Vicente
    Sugawara, Shunichi
    Cobo, Manuel Angel
    Perol, Maurice
    Mascaux, Celine
    Poddubskaya, Elena
    Kitazono, Satoru
    Hayashi, Hidetoshi
    Sands, Jacob
    Hall, Richard
    Zhang, Yong
    Zebger-Gong, Hong
    Uema, Deise
    Okamoto, Isamu
    Reinmuth, Niels
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 245 - 245
  • [3] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPIONLung01
    Atmaca, A.
    Ahn, M.
    Lisberg, A.
    Paz-Ares, L.
    Cornelissen, R.
    Girard, N.
    Pons-Tostivint, E.
    Baz, D.
    Sugawara, S.
    Cobo, M.
    Perol, M.
    Mascaux, C.
    Poddubskaya, E.
    Kitazono, S.
    Hayashi, H.
    Sands, J.
    Hall, R.
    Zhang, Y.
    Zebger-Gong, H.
    Okamoto, I
    Schumann, C.
    PNEUMOLOGIE, 2024, 78 : S99 - S99
  • [4] A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).
    Yoh, Kiyotaka
    Goto, Yasushi
    Thomas, Michael
    Spira, Alexander I.
    Sands, Jacob
    Johnson, Melissa Lynne
    Greenberg, Jonathan
    Petrich, Adam Matthew
    Guevara, Ferdinand M.
    Phillips, Penny
    Alexandris, Ekaterine
    Gu, Jessie
    Zhang, Yong
    Shuster, Dale Edward
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
    Ahn, Myung-Ju
    Tanaka, Kentaro
    Paz-Ares, Luis
    Cornelissen, Robin
    Girard, Nicolas
    Pons-Tostivint, Elvire
    Vicente Baz, David
    Sugawara, Shunichi
    Cobo, Manuel
    Perol, Maurice
    Mascaux, Celine
    Poddubskaya, Elena
    Kitazono, Satoru
    Hayashi, Hidetoshi
    Hong, Min Hee
    Felip, Enriqueta
    Hall, Richard
    Juan-Vidal, Oscar
    Brungs, Daniel
    Lu, Shun
    Garassino, Marina
    Chargualaf, Michael
    Zhang, Yong
    Howarth, Paul
    Uema, Deise
    Lisberg, Aaron
    Sands, Jacob
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
  • [6] Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01
    Pons-Tostivint, E.
    Okamoto, I.
    Sands, J.
    Girard, N.
    Cornelissen, R.
    Hong, M. H.
    Paz-Ares, L. G.
    Vicente Baz, D.
    Sugawara, S.
    Cobo Dols, M.
    Perol, M.
    Mascaux, C.
    Kitazono, S.
    Hayashi, H.
    Lisberg, A. E.
    Juan Vidal, O. J.
    Zhang, Y.
    Chargualaf, M.
    Uema, D.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2024, 35 : S835 - S836
  • [7] TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
    Kitazono, S.
    Paz-Ares, L.
    Ahn, M-J.
    Lisberg, A. E.
    Cho, B. C.
    Blumenschein, G.
    Shum, E.
    Pons-Tostivint, E.
    Goto, Y.
    Yoh, K.
    Heist, R.
    Baas, P.
    Planchard, D.
    Perol, M.
    Felip, E.
    Su, W-C.
    Zebger-Gong, H.
    Lan, L.
    Liu, C.
    Sands, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1671 - S1672
  • [8] TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
    Atmaca, Akin
    Paz-Ares, Luis
    Ahn, Myung-Ju
    Lisberg, Aaron
    Kitazono, Satoru
    Cho, Byoung Chul
    Blumenschein, George, Jr.
    Shum, Elaine
    Tostivint, Elvire Pons
    Goto, Yasushi
    Yoh, Kiyotaka
    Heist, Rebecca
    Baas, Paul
    Planchard, David
    Perol, Maurice
    Felip, Enriqueta
    Su, Wu-Chou
    Zebger-Gong, Hong
    Lan, Lan
    Liu, Chelsea
    Sands, Jacob
    Reinmuth, Niels
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 127 - 127
  • [9] Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
    Garon, E. B.
    Johnson, M. L.
    Lisberg, A. E.
    Spira, A.
    Yamamoto, N.
    Heist, R. S.
    Sands, J. M.
    Yoh, K.
    Meric-Bernstam, F.
    Kitazono, S.
    Greenberg, J.
    Kobayashi, F.
    Kawasaki, Y.
    Jukofsky, L.
    Nakamura, K.
    Shimizu, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1326 - S1327
  • [10] TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
    Ahn, M-J.
    Cho, B. C.
    Goto, Y.
    Yoh, K.
    Su, W-C.
    Shimizu, J.
    Lee, J-S.
    Oizumi, S.
    Yang, J. C-H.
    Hayashi, H.
    Zebger-Gong, H.
    Sugiura, K.
    Lan, L.
    Liu, C.
    Kitazono, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1684 - S1685
12345